Drug-resistant tumors are also able to activate the cMET pathway through increased cMET expression and/or increased cMET ligand expression, which provides an alternative mechanism for tumor cells to bypass the TKI blockade of EGFR and promote cancer cell survival (33–36). This evidence concerns the gene EGFR and neoplasm.